{"ModuleTitle": "Company Description", "CompanyName": "Zogenix, Inc.", "Symbol": "ZGNX", "Address": "5959 HORTON STREET, SUITE 500, EMERYVILLE, California, 94608, United States of America", "Phone": "(510) 550-8300", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Zogenix, Inc. (Zogenix, We or the Company) is a global pharmaceutical company\r\ncommitted to developing and commercializing transformative therapies to improve\r\nthe lives of patients and their families living with rare diseases. We are\r\nprimarily focused on developing and commercializing two therapeutic product\r\ncandidates: Fintepla, a low-dose fenfluramine, for two pediatric epilepsy\r\ndisorders and MT1621 for a mitochondrial depletion disorder.\r\nWe own and control worldwide development and commercialization rights to\r\nFintepla, our lead product candidate, for which we have filed a new drug\r\napplication (NDA) with the United States Food and Drug Administration (FDA)\r\nseeking approval to market and sell the product in the treatment of Dravet\r\nsyndrome, a rare and devastating pediatric epilepsy disorder. In March 2019, we\r\nentered into an exclusive distribution agreement with Nippon Shinyaku Co., Ltd.\r\nto support the sales and distribution of the product in Japan, if approved.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f02%2f0001375151-20-000011.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Bradley S. Galer", "title": "Chief Medical Officer & Executive Vice President"}, {"name": "Michael Patrick Smith", "title": "Chief Financial Officer, Treasurer & Executive VP"}, {"name": "Stephen James Farr", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}